Lixte Biotechnology Holdings, Inc. – NASDAQ:LIXTW

Lixte Biotechnology Holdings stock price today

$0.19
+0.16
+559.72%
Financial Health
0
1
2
3
4
5
6
7
8
9

Lixte Biotechnology Holdings stock price monthly change

-65.84%
month

Lixte Biotechnology Holdings stock price quarterly change

-65.84%
quarter

Lixte Biotechnology Holdings stock price yearly change

-30.95%
year

Lixte Biotechnology Holdings key metrics

Market Cap
80.73K
Enterprise value
N/A
P/E
N/A
EV/Sales
N/A
EV/EBITDA
N/A
Price/Sales
N/A
Price/Book
N/A
PEG ratio
N/A
EPS
-2.38
Revenue
N/A
EBITDA
-4.68M
Income
-4.69M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Lixte Biotechnology Holdings stock price history

Lixte Biotechnology Holdings stock forecast

Lixte Biotechnology Holdings financial statements

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXTW): Profit margin
Jun 2023 0 -1.66M
Sep 2023 0 -1.01M
Dec 2023 0 -1.03M
Mar 2024 0 -971.32K
Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXTW): Debt to assets
Jun 2023 3095148 402.61K 13.01%
Sep 2023 5234696 311.73K 5.96%
Dec 2023 4308620 313.85K 7.28%
Mar 2024 3589203 462.83K 12.9%
Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXTW): Cash Flow
Jun 2023 -1.17M 0 0
Sep 2023 -944.38K 0 3.13M
Dec 2023 -902.12K 3.13M 0
Mar 2024 -789.22K 0 0

Lixte Biotechnology Holdings alternative data

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXTW): Employee count
Jan 2024 3
Feb 2024 3
Mar 2024 3
Apr 2024 3
May 2024 3
Jun 2024 3
Jul 2024 3

Lixte Biotechnology Holdings other data

0.18% -0.55%
of LIXTW is owned by hedge funds
24.06K -74.05K
shares is hold by hedge funds
  • What's the price of Lixte Biotechnology Holdings stock today?

    One share of Lixte Biotechnology Holdings stock can currently be purchased for approximately $0.19.

  • When is Lixte Biotechnology Holdings's next earnings date?

    Unfortunately, Lixte Biotechnology Holdings's (LIXTW) next earnings date is currently unknown.

  • Does Lixte Biotechnology Holdings pay dividends?

    No, Lixte Biotechnology Holdings does not pay dividends.

  • How much money does Lixte Biotechnology Holdings make?

    Lixte Biotechnology Holdings has a market capitalization of 80.73K.

  • What is Lixte Biotechnology Holdings's stock symbol?

    Lixte Biotechnology Holdings, Inc. is traded on the NASDAQ under the ticker symbol "LIXTW".

  • What is Lixte Biotechnology Holdings's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Lixte Biotechnology Holdings?

    Shares of Lixte Biotechnology Holdings can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does Lixte Biotechnology Holdings have?

    As Jul 2024, Lixte Biotechnology Holdings employs 3 workers.

  • When Lixte Biotechnology Holdings went public?

    Lixte Biotechnology Holdings, Inc. is publicly traded company for more then 4 years since IPO on 27 Nov 2020.

  • What is Lixte Biotechnology Holdings's official website?

    The official website for Lixte Biotechnology Holdings is lixte.com.

  • How can i contact Lixte Biotechnology Holdings?

    Lixte Biotechnology Holdings can be reached via phone at +63 18307092.

Lixte Biotechnology Holdings company profile:

Lixte Biotechnology Holdings, Inc.

lixte.com
Exchange:

NASDAQ

Full time employees:

3

Industry:

Biotechnology

Sector:

Healthcare

Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to design novel compounds for serious common diseases. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.

680 East Colorado Boulevard
Pasadena, 91101

CIK: 0001335105
ISIN: US5393191110
CUSIP: 539319111